Stock listing

NASDAQ:IVVD Invivyd, Inc. Stock

Home listing (NASDAQ) of Invivyd, Inc.

Follow Invivyd, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IVVD

$0.413 USD -0.058 (-12.3%)

Close on Nov 20, 2026

Past year -82.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.413 – $0.467 USDNov 20, 2026
Volume
5.30M sharesNov 20, 2026
Market cap
$122.0M USDAt the close on Nov 20, 2026 · price × 295.6M shares outstanding
52-week range
$0.413 – $3.010 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.05M USDMedian day 4.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Invivyd, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IVVD · Home$0.413 USD-0.058 (-12.3%)5,296,603$0.440$0.467$0.413$0.471Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IVVD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.413-0.058-12.3%$0.440$0.467$0.4135,296,603
$0.471-0.042-8.2%$0.506$0.520$0.4656,706,811
$0.513-0.025-4.7%$0.545$0.556$0.4906,755,504
$0.538-0.044-7.6%$0.575$0.585$0.5203,279,698
$0.582+0.015+2.6%$0.574$0.589$0.5403,155,033
$0.567-0.032-5.3%$0.587$0.600$0.5512,602,791
$0.599+0.025+4.3%$0.591$0.610$0.5801,719,196
$0.574-0.022-3.7%$0.574$0.606$0.5552,867,660
$0.596+0.033+5.9%$0.562$0.614$0.5502,911,763
$0.563-0.022-3.8%$0.591$0.595$0.5602,335,444
$0.585-0.049-7.7%$0.635$0.640$0.5564,550,658
$0.634+0.052+9.0%$0.610$0.640$0.6034,434,486
$0.5820.000-0.1%$0.601$0.620$0.5589,316,999
$0.582+0.000+0.1%$0.598$0.600$0.5504,424,059
$0.582-0.020-3.4%$0.562$0.594$0.5385,361,494
$0.602-0.015-2.4%$0.610$0.635$0.5733,081,726
$0.617+0.028+4.7%$0.589$0.626$0.5772,895,195
$0.5890.000-0.1%$0.600$0.607$0.5804,248,537
$0.589-0.024-3.9%$0.630$0.630$0.5812,827,018
$0.613+0.003+0.5%$0.592$0.621$0.5802,762,894
$0.610-0.029-4.6%$0.644$0.663$0.5894,317,151
$0.639+0.003+0.4%$0.660$0.690$0.6356,022,757
$0.637+0.027+4.4%$0.622$0.651$0.6172,273,319
$0.610-0.009-1.5%$0.640$0.679$0.6104,484,895
$0.619-0.050-7.5%$0.670$0.680$0.6113,450,500
$0.669+0.061+10.0%$0.619$0.682$0.6143,285,300
$0.608-0.038-5.9%$0.640$0.640$0.6013,999,700
$0.646-0.027-4.1%$0.660$0.673$0.6403,657,067
$0.673-0.048-6.6%$0.710$0.717$0.6632,825,203
$0.721+0.021+3.0%$0.700$0.738$0.6912,765,900
$0.700-0.029-4.0%$0.740$0.740$0.67010,440,900
$0.729-0.077-9.6%$0.804$0.820$0.7259,468,300
$0.806-0.033-3.9%$0.852$0.854$0.8005,048,800
$0.839+0.017+2.1%$0.820$0.845$0.7905,422,400
$0.822+0.005+0.6%$0.835$0.844$0.7707,129,000
$0.817-0.053-6.1%$0.865$0.898$0.8065,459,800
$0.870+0.020+2.4%$0.855$0.879$0.8218,385,700
$0.850-0.100-10.5%$0.921$0.934$0.77431,292,500
$0.950+0.016+1.7%$0.976$1.010$0.94011,005,200
$0.934+0.021+2.3%$0.921$0.947$0.9013,489,300
$0.913-0.010-1.1%$0.950$0.970$0.8906,000,000
$0.923-0.041-4.3%$0.950$0.965$0.9116,910,200
$0.964-0.056-5.5%$1.010$1.010$0.9108,439,300
$1.020+0.265+35.1%$0.835$1.050$0.82015,009,500
$0.755+0.009+1.2%$0.756$0.786$0.7316,277,700
$0.746-0.059-7.3%$0.820$0.834$0.7305,840,500
$0.805-0.025-3.0%$0.830$0.840$0.8013,587,600
$0.830-0.062-7.0%$0.881$0.893$0.8204,231,000
$0.892+0.106+13.5%$0.820$0.936$0.8023,801,600
$0.786+0.010+1.3%$0.790$0.817$0.7714,383,700
$0.776-0.021-2.6%$0.782$0.815$0.7701,896,700
$0.797-0.029-3.5%$0.818$0.822$0.7831,906,100
$0.8260.0000.0%$0.849$0.863$0.8102,088,700
$0.826-0.009-1.1%$0.820$0.827$0.7901,960,300
$0.835+0.031+3.9%$0.835$0.847$0.8032,576,600
$0.804-0.076-8.6%$0.869$0.880$0.7804,988,000
$0.880-0.075-7.9%$0.860$0.901$0.75312,570,200
$0.955-0.010-1.0%$0.996$1.010$0.9423,495,200
$0.965+0.065+7.2%$0.910$0.970$0.8943,630,400
$0.900-0.002-0.2%$0.900$0.916$0.8791,718,900
$0.902-0.037-3.9%$0.923$0.923$0.8433,627,200
$0.939-0.004-0.4%$0.926$0.980$0.9222,851,300
$0.943-0.054-5.4%$0.970$0.975$0.9104,052,500
$0.997+0.046+4.8%$0.945$1.030$0.8665,426,100
$0.951-0.009-0.9%$1.015$1.050$0.9348,550,800
Ticker
NASDAQ:IVVD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Invivyd, Inc. news

Invivyd, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 138 in all · newest Nov 16, 2026 · oldest 2022
Calls
12 calls with a replay · 12 with a transcript · latest May 14, 2026
Decks
29 decks · latest Sep 29, 2026

Where Invivyd, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IVVD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IVVDBOATSUnited StatesUSD

Valuation

EV/sales 0.1× against a median of 2.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.86M USD
P/E
Loss
EV/sales
0.1×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
91.8%
Operating margin
−224.4%
Net margin
−214.8%
Debt to equity
0.1×
Beta vs S&P 500
2.06

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Invivyd, Inc. · NASDAQ:IVVDUS$122.0MUS$3.86Mn/a0.1×n/a0.8×−214.8%0.1×2.06
MacroGenics, Inc. · NASDAQ:MGNXUS$125.3M−US$127.6Mn/a−0.9×n/a5.0×−34.6%1.4×0.83
PolyPid Ltd. · NASDAQ:PYPDUS$124.3MUS$119.3Mn/an/an/a23.1×n/a0.3×0.93
Compass Therapeutics, Inc. · NASDAQ:CMPXUS$123.9M−US$29.89Mn/an/an/a0.9×n/a0.1×1.22
Humacyte, Inc. · NASDAQ:HUMAUS$123.7MUS$96.01Mn/a40.1×n/a6.8×n/a2.0×2.56
Biomm SA · BMFBOVESPA:BIOM3US$122.6MUS$136.5M18.4×2.1×12.3×2.2×10.3%0.3×n/a
Satellos Bioscience Inc · TSX:MSCLUS$121.9MUS$69.23Mn/an/an/a2.5×n/a0.0×0.49
Alar Pharmaceuticals Inc · TPEX:6785US$121.0MUS$51.66Mn/a568×n/a1.7×n/a0.0×n/a
CANbridge Pharmaceuticals Inc. · HKEX:1228US$120.4MUS$111.5Mn/a13.3×n/an/a−146.4%n/an/a
Atrium Therapeutics, Inc. · NASDAQ:RNAUS$118.4M−US$113.0Mn/a−2.9×n/a0.6×−229.7%0.0×0.76
Adagene, Inc. · NASDAQ:ADAGUS$118.2M−US$3.65Mn/a−0.5×n/a1.1×−229.6%0.1×1.43
Median of the othersUS$122.3MUS$60.45M18.4×2.1×12.3×2.2×−146.4%0.1×0.93

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.57 · 1 analyst
Revenue, year to Dec 2026
60.33M · 3 analysts

Team and board

Officers

OfficerRole
Marc EliaChairman of the Board and Chief Executive Officer
William DukeChief Financial Officer
Jill AndersenChief Legal Officer & Corporate Secretary
Rachael GerlachSenior Vice President of Regulatory Affairs
Julie GreenChief Human Resources Officer
Michael MinaChief Medical Officer and Chief Epidemiologist
Robert AllenChief Scientific Officer
Timothy LeeChief Commercial Officer

Board

DirectorRole
Marc EliaChairman of the Board and Chief Executive Officer
Ajay RoyanLead Independent Director
Ian SheffieldDirector
Kevin F. McLaughlinDirector
Paul B. BolnoDirector
Tamsin BerryDirector
Terrance McGuireDirector

Events

Calls

CallWhenStatus
Invivyd (NASDAQ:IVVD) Q1 2026 Earnings CallThu, May 14, 2026 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q4 2025 Earnings CallThu, Mar 05, 2026 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q1 2025 Earnings CallThu, May 15, 2025 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q3 2024 Earnings CallThu, Nov 14, 2024 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q2 2024 Earnings CallWed, Aug 14, 2024 · 8:30 AM ETReplay
Invivyd (NASDAQ:IVVD) Q1 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
Invivyd (NASDAQ:IVVD) Q3 2023 Earnings CallThu, Nov 09, 2023 · 4:30 PM ETReplay
Invivyd (NASDAQ:IVVD) Q2 2023 Earnings CallThu, Aug 10, 2023 · 4:30 PM ETReplay
Invivyd (NASDAQ:IVVD) Q1 2023 Earnings CallThu, May 11, 2023 · 4:30 PM ETReplay
All 12 calls
CallWhenStatus
Invivyd (NASDAQ:IVVD) Q4 2022 Earnings CallThu, Mar 23, 2023 · 4:30 PM ETReplay
Invivyd (NASDAQ:IVVD) Q3 2022 Earnings CallThu, Nov 10, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−7.6%
Q2 2026Aug 13, 2026 · After close+5.1%
Q1 2026May 14, 2026 · Before open−21.1%
Q4 2025Mar 26, 2026−12.2%
Q3 2025Nov 6, 2025 · Before open+1.3%
Q2 2025Aug 14, 2025 · After close−11.5%
Q1 2025May 15, 2025 · Before open−15.8%
Q4 2024Mar 26, 2025 · Before open−6.7%
Q3 2024Nov 14, 2024 · Before open−11.2%
Q2 2024Aug 14, 2024 · Before open−7.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−6.6%
Q4 2023Mar 28, 2024 · Before open+11.0%
Q3 2023Nov 9, 2023 · After close0.0%
Q2 2023Aug 10, 2023 · After close+3.2%
Q1 2023May 11, 2023 · After close+0.7%
Q4 2022Mar 23, 2023 · After close−8.4%
Q3 2022Nov 10, 2022 · After close+1.1%
Q2 2022Aug 15, 2022 · Before open0.0%
Q1 2022May 13, 2022 · Before open+2.3%
Q4 2021Mar 30, 2022 · Before open+30.4%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (September 2026)Corporate update23 slidesSep 29, 2026
Q1 2026 Earnings PresentationEarnings25 slidesMay 14, 2026
Corporate Update (April 2026)Corporate update19 slidesApr 9, 2026
Q4 2025 Earnings PresentationEarnings17 slidesMar 5, 2026
World Vaccine Congress Washington 2026Conference29 slidesMarch 2026
Investor Presentation (January 2026)Investor deck31 slidesJan 8, 2026
Q3 2025 Earnings PresentationEarnings23 slidesNov 6, 2025
Investor Presentation (October 2025)Investor deck38 slidesOct 30, 2025
Investor Presentation (August 2025)Investor deck24 slidesAug 14, 2025
Q1 2025 Earnings PresentationEarnings39 slidesMay 15, 2025
All 29 decks
DeckKindSlidesDate
Q3 2024 Earnings PresentationEarnings17 slidesNov 14, 2024
IDWeek 2024Conference23 slidesOct 16, 2024
Investor Presentation (September 2024)Investor deck27 slidesSep 6, 2024
Corporate Update (August 2024)Corporate update17 slidesAug 27, 2024
Q2 2024 Earnings PresentationEarnings29 slidesAug 14, 2024
Q1 2024 Earnings PresentationEarnings22 slidesMay 9, 2024
Corporate Update (April 2024)Corporate update9 slidesApr 4, 2024
Corporate Update (March 2024)Corporate update24 slidesMar 25, 2024
Investor Presentation (January 2024)Investor deck18 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings11 slidesNov 9, 2023
Investor Presentation (September 2023)Investor deck21 slidesSep 11, 2023
Investor Presentation (June 2023)Investor deck18 slidesJun 29, 2023
Investor Presentation (May 2023)Investor deck17 slidesMay 2, 2023
TD Cowen 43rd Annual Health Care Conference (March 2023)Conference14 slidesMar 6, 2023
J.P. Morgan 41st Annual Healthcare Conference 2023Conference10 slidesJan 9, 2023
Adagio Therapeutics — Investor Presentation (September 2022)Investor deck27 slidesSep 12, 2022
Technical Presentation (April 2022)Technical4 slidesApril 2022
Technical Presentation (2022)Technical4 slides2022
Technical Presentation (July 2021)Technical12 slidesJuly 2021

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$125M · US$2.5 a share · Cantor +1
Dealers: Cantor (lead), H.C. Wainwright & Co.
Use of proceeds: Commercial preparedness for potential VYD2311 launch, R&D on RSV and measles programs, SPEAR Study Group efforts, working capital and general corporate purposes
Nov 18, 2025
At-the-market programme of at-the-market (ATM) offering facility
Closed: US$29.8M raised
Nov 6, 2025
Public offering of common stock and pre-funded warrants
Closed: US$57.5M raised · US$0.52 a share · Cantor
Dealers: Cantor (lead)
Buyers: RA Capital Management; Janus Henderson Investors
Use of proceeds: VYD2311 clinical program, RSV and measles pipeline R&D, SPEAR Study Group efforts, working capital and general corporate purposes
Aug 22, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Adagio Therapeutics, Inc. Priced at US$17.00 a share on Aug 5, 2021.

Price
US$17.00 a share
Shares offered
18,200,000 shares of common stock
Offering size
US$309.4 million
Underwriters' option
Up to 2,730,000 more shares
Underwriters
MORGAN STANLEY, JEFFERIES, STIFEL, GUGGENHEIM SECURITIES · In the order on the cover
Shares delivered
On or about Aug 10, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 21, 2021
Filed publiclyJul 16, 2021
Amended twiceNewest Aug 4, 2021
Shares registered with an exchangeAug 3, 2021
Declared effective by the SECAug 5, 2021
Final prospectus, with the priceAug 6, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Aug 6, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2021FY2021FY2021FY2020
Revenue53.4M25.4M000
Cost of revenue3.75M1.62M2.03M462.0K1.00K
Gross profit49.7M23.8M-2.03M-462.0K-1.00K
Research and development38.3M137.3M158.7M179.2M182.9M106.5M
Selling, general and administrative66.9M63.4M49.1M47.0M36.5M
Operating income-55.6M-176.9M-212.8M-248.0M-226.9M-112.0M
Depreciation and amortization2.11M3.11M480.0K41.0K1.00K43.2M
EBITDA-53.5M-173.8M-212.3M-248.0M-226.9M-68.8M
Interest expense43.1M15.0M
Income before tax-52.5M-169.9M-198.6M-241.3M-226.8M-112.0M
Income tax00000-43.2K
Net income-52.5M-169.9M-198.6M-241.3M-226.8M-143.7M-83.4M-38.7M-112.0M
Earnings per share, basic-0.30-1.43-1.81-2.23-5.32-1.29-14.89-1.01
Earnings per share, diluted-0.30-1.43-1.81-2.23-5.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2021FY2021FY2021FY2020
Cash and equivalents226.7M69.3M200.6M92.1M542.2M478.3M392.5M91.2M115.0M
Short-term investments0279.9M49.2M0
Receivables13.9M10.9M0377.0K229.0K
Inventory25.5M25.9M0-377.0K-229.0K
Current assets247.5M100.7M224.9M376.9M616.7M680.2M396.1M117.4M
Property, plant and equipment1.36M1.51M1.90M2.28M83.0K
Total assets276.9M129.5M229.2M383.2M620.1M686.3M398.0M117.4M
Accounts payable13.7M10.4M7.95M1.52M5.78M17.6M10.7M8.15M
Current liabilities34.2M62.0M50.3M25.0M62.1M53.0M37.9M13.1M
Total debt2.49M1.30M2.17M3.72M
Total liabilities35.3M62.0M51.7M27.2M62.1M53.1M37.9M182.6M
Shareholders' equity241.5M67.5M177.5M356.0M558.0M633.2M-144.6M-103.4M-65.2M
Shares outstanding282.0M119.8M110.2M109.0M110.8M111.3M5.60M0111.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-58.1M-170.5M-173.2M-220.0M-184.7M-14.6M
Capital spending-155.0K-140.0K-615.0K-1.71M-84.0K-84.0K
Free cash flow-58.3M-170.6M-173.8M-221.7M-184.8M-14.6M
Cash from investing-155.0K-140.0K280.7M-230.7M-50.7M-50.7M
Cash from financing215.6M39.3M1.04M506.0K662.7M129.6M
Share buybacks-633.0K0-1.00K-4.00K0-3.00K
Change in cash157.3M-131.3M108.6M-450.1M427.2M115.0M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
8-K · Current reportSep 29, 2026Current reportSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
8-K · Current reportSep 1, 2026Management or board changeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
8-K · Current reportJul 24, 2026Current reportSEC
8-K · Current reportJul 6, 2026Current reportSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 14, 2026Offer documentSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportApr 9, 2026Current reportSEC
ARS · Annual report to shareholdersApr 6, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 6, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 29, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
8-K · Current reportDec 23, 2025Current reportSEC
CORRESP · Letter to the SECDec 19, 2025Other filingsSEC
S-3/A · Registration statement, amendedDec 19, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 25, 2025Big-stake noticeSEC
8-K · Current reportNov 24, 2025Current reportSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
8-K · Current reportNov 19, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 19, 2025Big-stake noticeSEC
424B5 · ProspectusNov 18, 2025Offer documentSEC
FWP · Free writing prospectusNov 17, 2025Offer documentSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
424B5 · ProspectusNov 17, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 30, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 22, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 14, 2025Big-stake noticeSEC
8-K · Current reportOct 6, 2025Current reportSEC
S-3 · Registration statementOct 2, 2025Offer documentSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2025Insider tradeSEC
8-K · Current reportSep 24, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeSep 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 27, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 26, 2025Big-stake noticeSEC
8-K · Current reportAug 22, 2025Material contractSEC
424B5 · ProspectusAug 22, 2025Offer documentSEC
FWP · Free writing prospectusAug 20, 2025Offer documentSEC
424B5 · ProspectusAug 20, 2025Offer documentSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportJul 2, 2025Current reportSEC
8-K · Current reportJun 26, 2025Current reportSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
8-K · Current reportMay 20, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportMay 12, 2025Current reportSEC
8-K · Current reportApr 25, 2025Current reportSEC
8-K · Current reportApr 21, 2025Material contractSEC
ARS · Annual report to shareholdersApr 7, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 7, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 7, 2025Meeting noticeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 26, 2025Insider tradeSEC
8-K · Current reportMar 26, 2025Management or board changeSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
8-K · Current reportMar 5, 2025Current reportSEC
8-K · Current reportFeb 24, 2025Current reportSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025ResultsSEC
8-K · Current reportJan 27, 2025Current reportSEC
8-K · Current reportJan 10, 2025Current reportSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
8-K · Current reportDec 27, 2024Current reportSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
144 · Notice of proposed saleDec 20, 2024Other filingsSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 12, 2024Big-stake noticeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
144 · Notice of proposed saleDec 9, 2024Other filingsSEC
8-K · Current reportDec 2, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
8-K · Current reportOct 29, 2024ResultsSEC
8-K · Current reportSep 23, 2024Current reportSEC
8-K · Current reportSep 6, 2024Current reportSEC
8-K · Current reportSep 4, 2024Current reportSEC
8-K · Current reportSep 3, 2024Current reportSEC
8-K · Current reportAug 27, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K · Current reportJun 14, 2024Current reportSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
8-K · Current reportMay 31, 2024Management or board changeSEC
144 · Notice of proposed saleMay 29, 2024Other filingsSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 22, 2024Meeting outcomeSEC
144 · Notice of proposed saleMay 16, 2024Other filingsSEC
S-8 · Registration statement for employee plansMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
8-K · Current reportMay 7, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 22, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 18, 2024Annual reportSEC
CORRESP · Letter to the SECApr 18, 2024Other filingsSEC

This page holds 200 of 452 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Invivyd, Inc.’s releases · as of Oct 29, 2026

Common shares
295,632,147
Fully diluted
295,632,147

Fully diluted

LineSharesAs of
Common shares295,632,147Oct 29, 2026

Share count over time

CountShares
Oct 29, 2026295,632,147
Sep 30, 2026295,632,147

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Janus Henderson36M12.2%US$31.4MSep 30, 2026
Bvf Inc28.2M9.5%US$24.5MSep 30, 2026
Maverick Capital LTD24.4M8.3%US$21.3MSep 30, 2026
BlackRock16.6M5.6%US$14.4MSep 30, 2026
Vanguard14.3M4.8%US$12.4MSep 30, 2026
Perceptive Advisors LLC13.8M4.7%US$12MSep 30, 2026
M28 Capital Management LP9.25M3.1%US$8.05MSep 30, 2026
Soleus Capital Management, L.P.7.52M2.5%US$6.55MSep 30, 2026
Point72 Asset Management, L.P.6.88M2.3%US$5.99MSep 30, 2026
Morgan Stanley5.94M2.0%US$5.17MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital5.61M1.9%US$4.88MSep 30, 2026
Siren, L.L.C.5M1.7%US$4.35MSep 30, 2026
Driehaus Capital Management LLC4.81M1.6%US$4.18MSep 30, 2026
State Street3.72M1.3%US$3.23MSep 30, 2026
Adage Capital Partners Gp, L.L.C.3.66M1.2%US$3.19MSep 30, 2026
Ikarian Capital, LLC2.66M0.90%US$2.31MSep 30, 2026
Citadel2.36M0.80%US$2.05MSep 30, 2026
Redmile Group, LLC2.29M0.77%US$1.99MSep 30, 2026
Eversept Partners, LP2.23M0.75%US$1.94MSep 30, 2026
Goldman Sachs1.99M0.67%US$1.73MSep 30, 2026
Qube Research & Technologies Ltd1.88M0.64%US$1.64MSep 30, 2026
Northern Trust1.72M0.58%US$1.5MSep 30, 2026
ADAR1 Capital Management, LLC1.67M0.56%US$1.45MSep 30, 2026
AQR Capital Management LLC1.39M0.47%US$1.21MSep 30, 2026
Ensign Peak Advisors, Inc1.36M0.46%US$1.18MSep 30, 2026
Boothbay Fund Management, LLC1.01M0.34%US$881KSep 30, 2026
Renaissance Technologies944K0.32%US$821KSep 30, 2026
UBS798K0.27%US$694KSep 30, 2026
DWS765K0.26%US$665KSep 30, 2026
Schwab698K0.24%US$608KSep 30, 2026
Two Sigma610K0.21%US$531KSep 30, 2026
BNY576K0.19%US$501KSep 30, 2026
Invesco535K0.18%US$466KSep 30, 2026
XTX Topco Ltd478K0.16%US$416KSep 30, 2026
Susquehanna467K0.16%US$406KSep 30, 2026
JPMorgan455K0.15%US$387KSep 30, 2026
Emerald Mutual Fund Advisers Trust429K0.15%US$373KSep 30, 2026
Virtus Investment Advisers, LLC412K0.14%US$359KSep 30, 2026
Cantor Fitzgerald, L. P.400K0.14%US$348KSep 30, 2026
Nuveen280K0.09%US$244KSep 30, 2026
ArchPoint Investors273K0.09%US$238KSep 30, 2026
Barclays231K0.08%US$201KSep 30, 2026
Bank of America204K0.07%US$177KSep 30, 2026
Rhumbline Advisers199K0.07%US$173KSep 30, 2026
Walleye Capital LLC197K0.07%US$171KSep 30, 2026
T. Rowe Price173K0.06%US$151KSep 30, 2026
Commonwealth Equity Services, LLC162K0.05%US$141KSep 30, 2026
Fidelity153K0.05%US$133KSep 30, 2026
Simon Quick Advisors, LLC138K0.05%US$120KSep 30, 2026
Miller Financial Services LLC130K0.04%US$113KSep 30, 2026

This page holds 50 of 131 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund7.79M2.6%US$6.79MJun 30, 2026
iShares Russell 2000 ETF5.37M1.8%US$4.69MJun 30, 2026
Vanguard Extended Market Index Fund2.38M0.81%US$2.08MJun 30, 2026
Fidelity Small Cap Index Fund2.29M0.77%US$1.22MJul 31, 2026
iShares Russell 2000 Value ETF2.03M0.69%US$1.77MJun 30, 2026
Fidelity Extended Market Index Fund1.1M0.37%US$1.26MMay 31, 2026
iShares Micro-Cap ETF706K0.24%US$616KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF586K0.20%US$511KJun 30, 2026
Schwab Small-Cap Index Fund538K0.18%US$288KJul 31, 2026
Emerald Growth Fund429K0.15%US$600KApr 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Emerald Growth Fund429K0.15%US$229KJul 31, 2026
Virtus Biotech Clinical Trials Etf404K0.14%US$216KJul 31, 2026
Master Small Cap Index Series393K0.13%US$343KJun 30, 2026
Fidelity Total Market Index Fund390K0.13%US$445KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF353K0.12%US$189KJul 31, 2026
Fidelity Series Total Market Index Fund324K0.11%US$369KMay 31, 2026
Fidelity Small Cap Value Index Fund293K0.10%US$256KJun 30, 2026
Nuveen Small Cap Blend Index Fund280K0.09%US$150KJul 31, 2026
EQ/2000 Managed Volatility Portfolio229K0.08%US$200KJun 30, 2026
Fidelity Nasdaq Composite Index Fund170K0.06%US$194KMay 31, 2026
LVIP State Street Small-Cap Index Fund158K0.05%US$138KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund140K0.05%US$122KJun 30, 2026
Vanguard Balanced Index Fund137K0.05%US$119KJun 30, 2026
Small Cap Index Fund110K0.04%US$96,234Jun 30, 2026
Global X Russell 2000 ETF101K0.03%US$53,789Jul 31, 2026
Ultra-Small Company Market Fund93,4000.03%US$81,482Jun 30, 2026
MetLife Russell 2000 Index Portfolio75,8060.03%US$66,133Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio69,6000.02%US$60,719Jun 30, 2026
Small-Cap Index Portfolio61,5940.02%US$53,735Jun 30, 2026
EQ/Small Company Index Portfolio57,7000.02%US$50,337Jun 30, 2026
EQ/AB Small Cap Growth Portfolio57,7000.02%US$50,337Jun 30, 2026
1290 VT Micro Cap Portfolio47,4290.02%US$41,377Jun 30, 2026
NVIT Small Cap Index Fund47,3420.02%US$41,301Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio47,2090.02%US$41,185Jun 30, 2026
Tiff Multi-Asset Fund45,2940.02%US$39,514Jun 30, 2026
Small Cap Index Trust44,6340.02%US$38,939Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund43,9650.01%US$38,355Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund42,8550.01%US$22,927Jul 31, 2026
1290 VT Small Cap Value Portfolio33,1910.01%US$28,956Jun 30, 2026
DWS Small Cap Index VIP33,0040.01%US$28,793Jun 30, 2026
T. Rowe Price Small-Cap Index Fund31,7340.01%US$27,685Jun 30, 2026
BlackRock Small Cap Index V.I. Fund28,807<0.01%US$25,131Jun 30, 2026
Victory Extended Market Index Fund27,058<0.01%US$14,476Jul 31, 2026
Voya RussellTM Small Cap Index Portfolio25,659<0.01%US$22,385Jun 30, 2026
SA Small Cap Index Portfolio24,648<0.01%US$13,187Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio19,102<0.01%US$16,665Jun 30, 2026
Nationwide Small Cap Index Fund19,100<0.01%US$10,219Jul 31, 2026
SmallCap Value Fund II17,158<0.01%US$9,180Jul 31, 2026
Venerable Small Cap Index Fund16,822<0.01%US$14,676Jun 30, 2026
PD Small-Cap Value Index Portfolio16,145<0.01%US$14,085Jun 30, 2026

This page holds 50 of 71 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Allen Robert D. III
Officer: Chief Scientific Officer
Sale17,043USD 0.84US$14,316Aug 18, 2026
Andersen Jill
Officer: Chief Legal Officer, Secretary
Sale30,706USD 0.84US$25,793Aug 18, 2026
Duke William E.
Officer: Chief Financial Officer
Sale18,425USD 0.84US$15,477Aug 18, 2026
Green Julie
Officer: Chief Human Resources Officer
Sale18,425USD 0.84US$15,477Aug 18, 2026
Lee Timothy Edward
Officer: Chief Commercial Officer
Sale18,425USD 0.84US$15,477Aug 18, 2026
Allen Robert D. III
Officer: Chief Scientific Officer
Sale20,679USD 0.72US$14,889Aug 17, 2026
Andersen Jill
Officer: Chief Legal Officer, Secretary
Sale37,256USD 0.72US$26,824Aug 17, 2026
Duke William E.
Officer: Chief Financial Officer
Sale22,355USD 0.72US$16,096Aug 17, 2026
Green Julie
Officer: Chief Human Resources Officer
Sale22,355USD 0.72US$16,096Aug 17, 2026
Lee Timothy Edward
Officer: Chief Commercial Officer
Sale22,355USD 0.72US$16,096Aug 17, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC12.10%25.4MSep 30, 2025Schedule 13G
BVF PARTNERS L P/IL9.99%29.6MJun 30, 2026Schedule 13G
Maverick Capital LTD8.30%24.4MSep 30, 2026Schedule 13G
Adimab, LLC7.30%20.3MDec 23, 2025Schedule 13D
Ra Capital Management, L.P.7.00%21.3MMar 31, 2026Schedule 13G
BlackRock, Inc.5.50%16.1MJun 30, 2026Schedule 13G
Mithril II LP4.80%11.2MAug 22, 2025Schedule 13D
Marc Elia4.60%9.55MAug 22, 2025Schedule 13D
Terrance McGuire3.00%7.01MAug 22, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael Wyzga
Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Mereo BioPharma Group plc (Chairman of the Board · Since at least Jan 1, 2024); X4 Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2019); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past); EXACT Sciences Corporation (Director · Feb 9, 2015 – Feb 26, 2021 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past); OncoMed Pharmaceuticals Inc (Director · Oct 14, 2013 – Jun 22, 2018 · Past); Idenix Pharmaceuticals Inc (Director · Mar 1, 2012 – Aug 5, 2014 · Past); Radius Health, Inc. (Chief Executive Officer, Director · Dec 5, 2011 – Dec 15, 2011 · Past); Genzyme Corp (Executive VP and CFO · May 25, 2006 – Apr 4, 2011 · Past)
Director · Aug 5, 2021 – May 23, 2023 · Past
Frederick W. Driscoll
Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Feb 22, 2018); Cellectar Biosciences, Inc. (Director · Since at least Apr 10, 2017); ConforMIS Inc (INTERIM CFO & INTERIM TREAS · Oct 23, 2019 – Oct 23, 2019 · Past); Cue Biopharma, Inc. (Director · Jun 26, 2018 – Jan 2, 2025 · Past); ImmunityBio, Inc. (Director · Sep 18, 2017 – Aug 11, 2020 · Past); Flexion Therapeutics Inc (Chief Financial Officer · Feb 11, 2014 – Nov 19, 2021 · Past); Oncotelic Therapeutics Inc (Director · Jan 1, 2014 – Jun 1, 2016 · Past); Novavax, Inc. (VP, CFO & Treasurer · Aug 24, 2009 – Mar 2, 2013 · Past); Genelabs Technologies Inc (CEO/PRESIDENT · Nov 1, 2007 – Jan 7, 2009 · Past)
Interim CFO · Oct 13, 2022 – Oct 13, 2022 · Past
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Since at least Aug 5, 2021
Jane Pritchett Henderson
Other companies: CARGO Therapeutics, Inc. (Director · Since at least Jun 3, 2024); Apogee Therapeutics, Inc. (Chief Financial Officer · Since at least Jul 13, 2023); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Sesen Bio Inc (Director · Jun 12, 2018 – May 3, 2021 · Past); IVERIC bio Inc (Director · Jan 13, 2018 – Jul 11, 2023 · Past); Voyager Therapeutics, Inc. (Sr. V.P. & CFO, Corp. Dev. · Jan 1, 2017 – Mar 22, 2018 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – May 19, 2017 · Past)
Chief Financial Officer · Aug 5, 2021 – Jan 30, 2022 · Past
Clive Meanwell
Other companies: Metsera, Inc. (EXECUTIVE CHAIRMAN, Director · Since at least Jan 30, 2025); Fractyl Health, Inc. (Executive Chairman and Founder of Population Health Partners · Since at least Feb 1, 2024); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Population Health Investment Co Inc (Chief Executive Officer, Director · Nov 17, 2020 – Aug 24, 2021 · Past); The Medicines Company (Chief Innovation Officer, Director · Jul 1, 2015 – Jan 6, 2020 · Past)
Director · Jun 22, 2022 – May 23, 2023 · Past
Tomas J. Heyman
Other companies: Legend Biotech Corp. (Director · Since at least Mar 18, 2026); Exelixis, Inc. (Director · Since at least May 31, 2023); Akero Therapeutics Inc (Director · Since at least Jun 9, 2020); Xilio Therapeutics, Inc. (Director · Sep 15, 2022 – Jun 12, 2023 · Past); OptiNose (Director · Dec 1, 2020 – May 21, 2025 · Past)
Director · Aug 5, 2021 – May 23, 2023 · Past
Kevin F. McLaughlin
Other companies: Vericel Corporation (Director · Since at least Jan 6, 2015); Decibel Therapeutics Inc (Director · Oct 10, 2022 – Sep 25, 2023 · Past); Acceleron Pharma Inc (SVP, CFO and Treasurer · Jul 7, 2015 – Nov 19, 2021 · Past)
Director · Since at least May 21, 2024
William Duke
Other companies: Apexigen Inc. (Chief Financial Officer · Jul 29, 2022 – Aug 23, 2023 · Past); Kaleido Biosciences, Inc. (Chief Financial Officer · Nov 22, 2019 – Jan 14, 2022 · Past); Pulmatrix, Inc. (Chief Financial Officer · Jun 24, 2015 – May 16, 2019 · Past)
Chief Financial Officer · Since at least Sep 1, 2023
Howard Mayer
Other companies: PepGen Inc. (Non-Executive Director · Since at least Nov 10, 2023); Entasis Therapeutics Holdings Inc (Director · Aug 5, 2019 – Jul 7, 2022 · Past)
Director · Aug 5, 2021 – Jun 22, 2022 · Past
Ian Sheffield
Other companies: Fractyl Health, Inc. (Director · Since at least Sep 2, 2025); Apyx Medical Corporation (Director · Dec 13, 2013 – May 6, 2015 · Past)
Director · Since at least Aug 30, 2026
All 36 people
PersonSeat
René Russo
Other companies: Xilio Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 21, 2021); X4 Pharmaceuticals, Inc. (Director · Jun 17, 2019 – Jun 2, 2021 · Past)
Director · Aug 5, 2021 – Aug 5, 2021 · Past
Tillman U Gerngross
Other companies: Alector, Inc. (Director · Feb 6, 2019 – Jun 14, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past)
Chief Executive Officer, Director · Aug 5, 2021 – Jan 30, 2022 · Past
Ajay Royan
Other companies: Fractyl Health, Inc. (Director · Since at least Feb 1, 2024)
Lead Independent Director · Since at least Aug 5, 2021
Marc Elia
Other companies: Fractyl Health, Inc. (Founder of M28 Capital, Inc. · Since at least Feb 1, 2024)
Chairman of the Board and Chief Executive Officer · Since at least May 23, 2023
Michael Mina
Other companies: Quantum-Si Incorporated (Director · Jun 10, 2021 – May 12, 2023 · Past)
Chief Medical Officer and Chief Epidemiologist · Since Mar 5, 2026
Paul B. Bolno
Other companies: Wave Life Sciences Ltd. (President and Chief Executive Officer · Since at least Nov 10, 2015)
Director · Since at least Sep 22, 2025
Rebecca Dabora
Other companies: Apogee Therapeutics, Inc. (Chief Development Officer · Since at least Nov 4, 2026)
Chief Tech and Manuf Officer · Aug 5, 2021 – Dec 14, 2022 · Past
Redonda Miller
Other companies: Cencora, Inc. (Director · Since at least Jan 1, 2023)
Director · Nov 19, 2021 – Jun 22, 2022 · Past
Srishti Gupta
Other companies: NovaBridge Biosciences (Chief Executive Officer and Director · Since at least Jul 1, 2026)
Director · May 21, 2024 – May 21, 2024 · Past
Anand ShahDirector · Aug 5, 2021 – Aug 5, 2021 · Past
Christine LindenboomDirector · Oct 20, 2022 – May 20, 2025 · Past
David HeringChief Executive Officer, Director · Aug 5, 2021 – Dec 18, 2023 · Past
Elham HershbergerChief Development Officer · Aug 5, 2021 – Jan 30, 2022 · Past
Ellen R MarramDirector · Nov 19, 2021 – Nov 19, 2021 · Past
Jeremy GowlerCOO & CCO · Dec 18, 2023 – Dec 18, 2023 · Past
Jill AndersenChief Legal Officer & Corporate Secretary · Since at least Nov 1, 2021
Julie GreenChief Human Resources Officer · Since at least Jan 24, 2024
Lynn ConnollyChief Medical Officer · Aug 5, 2021 – Jan 30, 2022 · Past
Peter SchmidtChief Medical Officer · Dec 6, 2022 – Dec 18, 2023 · Past
Rachael GerlachSenior Vice President of Regulatory Affairs · Since at least Feb 3, 2026
Robert AllenChief Scientific Officer · Since at least May 14, 2026
Robert D Allen IIIChief Scientific Officer · Since at least Apr 11, 2023
Sara CotterDirector · Jul 25, 2023 – May 21, 2024 · Past
Stacy PriceChief Tech. and Manuf. Officer · Mar 27, 2023 – Dec 18, 2023 · Past
Tamsin BerryDirector · Since at least Jun 22, 2022
Timothy LeeChief Commercial Officer · Since at least Jun 5, 2024

Open People

Log in to ask 6ix AI your own questions about Invivyd, Inc.